Plerixafor/Tacrolimus Hydrate

普乐沙福/他克莫司水合物

Report date: 2026/03/30 17:02:26

Base Information

Drug NamePlerixafor/Tacrolimus Hydrate
Drug Alias NameMRG-001(MedRegen)AMD3100+FK506
ClassificationSmall moleculesSmall molecules > Molecular Glue
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonistsCalcineurin inhibitorsCytokines inhibitors +[6] 
TargetsC-X-C motif chemokine receptor 4CalcineurinFK506-binding protein 1A +[5] 
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Abdominal InjuriesWounds and Injuries +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsYes PlerixaforTacrolimus Hydrate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMedRegen LLC
China Registration ClassN/A

Develop Information

Active CompaniesMedRegen LLC
Inactive CompaniesN/A
Active IndicationsAbdominal InjuriesCytokine Release SyndromeMotor Neuron Disease +[7] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Wounds and InjuriesRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A